McKesson’s Practice Insights Designated as a 2026 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services

A decade of CMS recognition: Practice Insights continues to simplify Merit-based Incentive Payment System reporting for providers

IRVING, Texas--(BUSINESS WIRE)--For the tenth consecutive year, the Centers for Medicare & Medicaid Services (CMS) has named McKesson a Qualified Clinical Data Registry (QCDR) approved to participate in the Merit-based Incentive Payment System (MIPS).

As a CMS-approved QCDR, McKesson’s Practice Insights — a performance analytics tool powered by Ontada^®, McKesson’s real-world oncology data and insights business — collects and reports clinical data for clinicians using the IKnowMed^® electronic health record. The designation allows practices and providers to efficiently submit data for both MIPS and custom QCDR quality measures directly to CMS, eliminating the need for a separate registry vendor and reducing administrative burdens.

“McKesson is focused on empowering community oncology practices with insights that support patient care,” said Jason Hammonds, president, Oncology & Multispecialty, McKesson. “With a single, integrated pathway for submitting quality measures and action‑oriented analytics, our QCDR helps providers strengthen care delivery, track performance and enhance operations.”

McKesson’s Practice Insights offers nine oncology-specific QCDR measures to drive improvements in quality and cost of care. Seven of these measures were developed in collaboration with physicians in The US Oncology Network, an organization of community-based providers supported by McKesson:

• Screening and Achieving Resolution or Improvement of Distress for Cancer Care
• Advance Care Planning in Metastatic Cancer Patients
• Patient-Reported Pain Improvement
• Supportive Care Drug Utilization in Last 14 Days of Life
• Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs
• Mutation Testing for Stage IV Lung Cancer Completed Prior to the Start of Targeted Therapy
• Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy

Two additional measures were developed by the American Society of Clinical Oncology (ASCO) and have been approved for the fourth year:

• Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic — Avoidance of Overuse
• Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents

Additionally, CMS retained two Practice Insights QCDR measures for inclusion in the 2026 Advancing Cancer Care MIPS Value Pathways: Mutation Testing for Stage IV Lung Cancer and Utilization of Prophylactic GCSF for Patients Receiving Low-Risk Chemotherapy. This recognition underscores the value of McKesson’s quality measures for improving cancer care.

New for 2026 is a patient-reported outcome measure that tracks whether distress screening and follow-up interventions lead to meaningful improvement or resolution within six months. Distress includes physical, emotional, social, practical and spiritual concerns — key factors that affect patient well-being and treatment outcomes. By tracking this measure through McKesson’s Practice Insights’ QCDR, practices can gain insights into the effectiveness of psychosocial care, helping deliver timely interventions and enhanced patient support.

“This designation reflects our dedication to oncology-focused quality improvement,” explained Erin Crum, senior director, Quality Strategy and Innovation, McKesson and The US Oncology Network. “For 10 consecutive years, we’ve empowered practices with integrated tools to track performance, reduce reporting burdens and align with value-based care programs. Through efforts such as these, we continue to advance patient-centered, outcome-driven care.”

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.

About McKesson Oncology & Multispecialty

Our Oncology & Multispecialty segment delivers a portfolio of integrated solutions that support patient care by accelerating drug development, expanding access to high-quality care close to home and ensuring life-saving therapies reach the patients who need them most. We provide practice management, technology solutions, specialty drug distribution, clinical trial and group purchasing services, along with pharmacy solutions for community-based oncology practices and multispecialty providers in retina and ophthalmology. We partner behind the scenes with healthcare providers in local communities, supporting their operations so that they can stay focused on who matters most – patients.